The Indian drug regulator has approved Itolizumab to treat COVID-19 patients. (Representative)
New Delhi:
Indian drug regulator approved itolizumab, a drug used to treat psoriasis of skin conditions for “restricted emergency use” to treat COVID-19 patients with moderate to severe acute respiratory distress, said Friday officials at the PTI.
In view of the unmet medical needs to treat COVID-19, Dr VG Somani, General Drug Controller in India, approved the injection of Itolizumab monoclonal antibodies, a drug already approved by Biocon, for restricted emergency use for the treatment of “cytokine” release syndrome in moderate people. to patients with severe acute respiratory distress syndrome due to COVID-19, they said.
“The approval was given after its clinical trials on COVID-19 patients in India were judged satisfactory by the expert committee including pulmonologists, pharmacologists and medical experts from AIIMS, among others, to treating cytokine release syndrome, “an official told PTI.
“It is a drug approved by Biocon for the treatment of psoriasis for many years,” said the official.
Written informed consent from each patient is required before using this medication, he said.
(With the exception of the title, this story was not edited by GalacticGaming staff and is published from a syndicated feed.)
